Shots:
- Junshi Biosciences reported that the NMPA has accepted the NDA for roconkibart injection (JS005), for adults with moderate to severe plaque psoriasis eligible for systemic therapy or phototherapy
- The submission is backed by a multicenter P-III study (n=747) showing significant improvements in PASI 75/90/100 and sPGA 0/1 vs PBO at 12wks., with sustained efficacy through 52wks. and a favorable safety profile
- Roconkibart is a recombinant humanized anti-IL-17A mAb that works by specifically binding to IL-17A with high affinity, preventing it from interacting with its receptor complex IL-17RA/IL-17RC on target cells
Ref: GlobeNewswire | Image: Junshi Biosciences | Press Release
Related News: Junshi Biosciences Reports the NMPA’s sNDA Acceptance of Toripalimab + Disitamab Vedotin for Urothelial Carcinoma
PharmaShots, your go-to media platform for customized news across multiple therapeutic areas. For more information, reach us at connect@pharmashots.com
